Concepedia

Author

Rodica Morariu-Zamfir

Sanofi (France)

Also Known As

R Morariu-Zamfir, Rodica Morariu-Zamfir

19

Publications

523

Citations

9

H-Index

12

Concepts

All Affiliations

Sanofi (France)ImmunoGen (United States)Hôpital Edouard HerriotIncyte (United States)Massachusetts General Hospital
RM

About

Rodica Morariu-Zamfir is an author at Sanofi (France) specializing in immunology, oncology, and hematology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

148

2

Immunology

2

2

148

3

Health Sciences

1

1

104

4

Marrow Transplantation

1

1

44

5

Autoimmunity

1

1

44

Rodica Morariu-Zamfir

×

8

Publications

474

Citations

8

H-Index

YearCitations

Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma

Anas Younes, Stella Kim, Jorge Romaguera,

Journal of Clinical Oncology

2012

167

Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia

Simona Lapusan, María‐Belén Vídriales, Xavier Thomas,

Investigational New Drugs

2011

104

A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL

Natalie Dimier, Paul Delmar, Carol Ward,

Blood

2017

78

Influence of CD34+ marrow cell dose on outcome of HLA-identical sibling allogeneic bone marrow transplants in patients with chronic myeloid leukaemia

Rodica Morariu-Zamfir, Vanderson Rocha, A Devergié,

Bone Marrow Transplantation

2001

44

Phase I Multi-Dose Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous (IV) Infusion Every 3 Weeks to Patients with Relapsed/ Refractory B-Cell Non-Hodgkin's Lymphoma (NHL).

Anas Younes, Leo I. Gordon, Stella Kim,

Blood

2009

37

An Open Label, Dose Escalation Study of AVE9633 Administered as a Single Agent by Intravenous (IV) Infusion Weekly for 2 Weeks in 4-Week Cycle to Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia (AML).

Ollivier Legrand, María‐Belén Vídriales, Xavier Thomas,

Blood

2007

18

Itacitinib for the Prevention of Immune Effector Cell Therapy-Associated Cytokine Release Syndrome: Results from the Phase 2 Incb 39110-211 Placebo-Controlled Randomized Cohort

Matthew J. Frigault, Richard T. Maziarz, Jae H. Park,

Blood

2023

16

JAK1 Inhibition during CAR T-Cell Treatment Does Not Affect CAR T-Cell Proliferation, Persistence, or Function

Michael A. Pratta, Lea Burke, John F. DiPersio,

Blood

2022

10

Page 1